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Should we use SSRIs to treat 
adolescents with depression?
Yes.	based	on	current	evidence,	
fluoxetine	is	the	most	effective	selective	
serotonin	reuptake	inhibitor	(SSrI)	for	
treatment	of	major	depressive	disorder	in	
adolescents.	It	is	the	only	agent	approved	
by	the	uS	Food	and	Drug	Administration	
(FDA)	for	use	in	children	(strength	of	
recommendation	[Sor]:	A,	based	on	
meta-analysis	of	rCts).	
	 All	SSrI	medications	increase	the	
risk	of	suicidal	behavior	in	adolescents,	
but	do	not	increase	the	risk	of	completing	
suicide	(Sor:	A,	based	on	meta-analysis	
of	rCts).		
First, we must spot those at risk 
Family	physicians	are	often	the	primary	
providers	of	healthcare	for	adolescents.	
most	health	issues	affecting	this	unique	
population	are	social	and	behavioral	
in	origin.	by	routinely	incorporating	
prevention	and	screening	techniques	
into	the	adolescent	visit,	we	can	detect	
at-risk	individuals.	We	need	to	inquire	
about	sleep,	personal	interests,	eating	
behaviors,	future	plans,	friends	and	social	
activities,	school	performance,	mood,	
and	drug	and	alcohol	use	so	that	we	can	
detect	early	symptoms	of	depression.	
	 For	those	family	physicians	who	like	
reminders,	there	are	mnemonics	and	
questionnaires	that	evaluate	the	social	
and	behavioral	aspects	of	the	adolescent	
visit.	Family	physicians	should	also	
educate	parents	and	family	members	
about	depressive	signs	and	symptoms	
and	the	potential	warning	signs	of	
suicidality.	
Beth Fox, MD
east	tennessee	State	university,	Johnson	City
z 	Evidence summary
Major depressive disorder is common 
among adolescents and is associated 
with significant morbidity, including 
substance abuse and eating disorders. 
One study of survey data from 1769 
adolescents found a lifetime prevalence 
of 15.3% for major depression. The 
majority of those reporting episodes of 
major depression in this study had re-
current symptoms and impairment in 
work or school.1
Fluoxetine and therapy together 
have the best results 
A large, multicenter, randomized con-
trolled trial evaluated the effectiveness 
of fluoxetine (Prozac), cognitive behav-
ioral therapy (CBT), or the combina-
tion of the 2. Researchers evaluated 
improvement with the Children’s De-
pression Rating Scale–Revised (CDRS-
R). The CDRS-R uses adolescent and 
parent interviews to rate 17 symptom 
areas: impaired schoolwork, difficulty 
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having fun, social withdrawal, appe-
tite disturbance, sleep disturbance, ex-
cessive fatigue, physical complaints, 
irritability, excessive guilt, low self- 
esteem, depressed feelings, morbid ideas, 
suicidal ideas, excessive weeping, de-
pressed facial affect, listless speech, and 
hypoactivity. Combination treatment 
with fluoxetine and CBT was statisti-
cally superior to placebo, CBT alone, or 
fluoxetine alone. In addition, fluoxetine 
alone was superior to CBT alone.2 
A meta-analysis including both 
published and unpublished trials of 
SSRI medications found that fluoxetine 
was more likely than placebo to cause 
remission of symptoms after 7 to 8 
weeks of treatment (number needed to 
treat [NNT]=6). Fluoxetine treatment 
was also associated with a reduction in 
symptom scores as measured with the 
CDRS-R (NNT=5).3 
Data were conflicting for the ef-
ficacy of paroxetine (Paxil), sertraline 
(Zoloft), and citalopram (Celexa).3,4 No 
data were available for escitalopram 
(Lexapro). 
But are SSRIs safe  
for adolescents?
Considerable controversy surrounds the 
safety of SSRIs in children due to reports 
of increased suicidal behavior. In 2004, 
the FDA conducted a meta-analysis of 
the suicide related adverse events from 
the published and unpublished trials of 
SSRIs including fluoxetine, sertraline, 
paroxetine, fluvoxamine (Luvox), and 
citalopram. A team of experts reviewed 
the adverse events from each trial to 
evaluate for suicidality including sui-
cidal ideation, preparatory acts, self-
injurious behavior, or suicide attempts. 
They found a risk ratio of 1.66 (95% 
confidence interval, 1.02–2.68) for sui-
cidality in the treatment arms compared 
with placebo. There were no completed 
suicides in any study.5 
This review led to the FDA’s October 
2004 “black box” warning regarding 
suicidality and antidepressant medica-
tion in adolescents. However, an ecolog-
ical analysis of prescription data and US 
Census data found an overall decline in 
suicide rates as the rate of prescriptions 
for SSRI medications increased, sug-
gesting a beneficial correlation of SSRI 
medications on suicide rates.6
Recommendations from others
The American Academy of Child and 
Adolescent Psychiatry (AACAP) recom-
mends psychosocial and pharmacologic 
intervention for depression, with psycho-
therapy as the preferred initial treatment 
for most adolescent patients.4 This orga-
nization reviewed the current published 
and unpublished data including the FDA 
analysis to formulate its conclusions re-
garding safety and efficacy. AACAP con-
cluded that fluoxetine is effective for the 
treatment of depression in children and 
adolescents. n
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